IsoPSA leads to reduction in prostate biopsy recommendations

Video

“The idea is to develop strategies that reduce the likelihood of needing a biopsy or improving the sensitivity of the biopsy to find a high-grade cancer, one that's treatable,” says Eric A. Klein, MD.

In this video, Eric A. Klein, MD, gives an overview of the recent Urology Practice study “IsoPSA reduces provider recommendations for biopsy and magnetic resonance imaging in men with total prostate specific antigen ≥4 ng/mL: a real-world observational clinical utility study," for which he served as senior author. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.

Related Videos
Bree Duncan, RN, BSN, answers a question during a Zoom video interview
Orange pill bottle with loose pills spilling out | Image Credit: © Antonio Rodriguez - stock.adobe.com
A panel of 5 experts on prostate cancer
A panel of 5 experts on prostate cancer
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Heather L. Huelster, MD, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.